Skip header and navigation

6 records – page 1 of 1.

Document Type
Rapid Review
Review Code
PPE120901 RR
Question Submitted
December 9, 2020
Date Completed
December 18, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Document Type
Rapid Review
Review Code
PPE120901 RR
Question Submitted
December 9, 2020
Date Completed
December 18, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Key Findings
Moderate evidence supporting the concept that airway management and certain surgical procedures create aerosols
No definitive evidence for the transmission of SARS-CoV-2 during AGMP
Indirect evidence from SARS-CoV-1 indicates that HCW present during AGMP are at higher risk of infection, but evidence quality is very low and very difficult to generalize
The absence of definitive evidence does not equate to the absence of risk and most policy recommendations err on the side of safety for Health Care Workers
Category
Infection Prevention and Control
Subject
Aerosols
Risk
Transmission
Population
All
Clinical Setting
Ambulatory
Long Term Care
Priority Level
Level 2 One week (7 days)
Cite As
Badea, A; Groot, G; Fox, L; Mueller, M. What is the risk of COVID-19 transmission during AGMP procedures? 2020 Dec 18; Document no.: PPE120901 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 30 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC081401v2 RR
Question Submitted
August 14, 2020
Date Completed
December 1, 2020
Status
5. Updated review
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC081401v2 RR
Question Submitted
August 14, 2020
Date Completed
December 1, 2020
Status
5. Updated review
Research Team
EOC
Key Findings
In the absence of SARS-CoV-2 specific evidence, recommendations for fallow time following AGPs in the context of the SARS-CoV-2 pandemic range widely depending on country and specialty association.
The majority of recommendations are based upon dental practices and several on thoracic surgical practice.
The most common recommendations follow the CDC’s guidelines for airborne contamination removal based on air changes per hour ventilation properties of rooms.
Assuming that most treatment rooms have a minimum of 10-12 ACH, most associations recommend a 20-minute fallow periods, or 60 minutes if ACH is unknown or below recommendations for treatment rooms.
Category
Administration
Infection Prevention and Control
Subject
Aerosols
Facilities
Decision Making
Priority Level
Level 4 completed within 1 week
Cite As
Badea, A; Groot G; Dalidowicz, M; Young, C; Miller, L. What are the recommendations around settling times following aerosol generating procedures on suspected or confirmed COVID-19 patients? 2020 Dec 1; Document no.: EOC081401v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 24 p. (CEST rapid review report)
Review History
EOC081401 RR: August 24, 2020
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC090202 RR
Question Submitted
September 2, 2020
Date Completed
September 8, 2020
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC090202 RR
Question Submitted
September 2, 2020
Date Completed
September 8, 2020
Status
3. Completed
Research Team
EOC
Key Findings
· The Intubation box was originally invented by Dr. Lai Hsien-yung, an anesthesiologist in Taiwan. · The main function of the intubation box is intended to prevent exposure of care providers to COVID-19 from aerosol droplets during intubation. · The intubation box concept emerged during the pandemic to address the challenge of adequate supply of PPEs in resource limited settings in particular but presents limitations and poses significant safety risk to the patient. · limitations include increased incubation time, discomfort from restricted hand movements for the intubation procedure, reduced first-pass intubation rates, limitation for certain body habitus and possible injury to patient · With regards to aerosol exposure, intubation boxes have been reported to increase rather than decrease airborne particle exposure.
Category
Administration
Infection Prevention and Control
Subject
Intubation
Risk
Personal Protective Equipment
Aerosols
Transmission
Population
All
Priority Level
Level 3 completed within 2-3 days
Cite As
Asamoah, G; Groot, G; Badea, A; Ellsworth, C; Fox, L. What are the safety risks or disinfection concerns with the use of intubation boxes? 2020 Sep 8; Document no.: EOC090202 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 13 p. (CEST rapid review report)
Similar Reviews
EOC033001 RR
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC051201 RR
Question Submitted
May 12, 2020
Date Completed
May 15, 2020
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC051201 RR
Question Submitted
May 12, 2020
Date Completed
May 15, 2020
Status
3. Completed
Research Team
EOC
Key Findings
· Small simulation studies have demonstrated potential contamination of neck and back area · Many associations recommend neck coverage, or if unavailable to ensure sanitation/washing of exposed skin after doffing PPE · Several warnings that increasing amount of PPE increases chances of contamination and may decrease level of compliance
Category
Infection Prevention and Control
Clinical Management
Subject
Personal Protective Equipment
Aerosols
Priority Level
Level 3 completed within 2-3 days
Cite As
Badea, A; Groot, G; Dalidowicz, M; Miller, L. Do neck or back coverings provide additional protection to gown and N95 mask when conducting an aerosol generating procedure? 2020 May 15; Document no.: EOC051201 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 9 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC040101 RR
Question Submitted
April 1, 2020
Date Completed
April 1, 2020
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC040101 RR
Question Submitted
April 1, 2020
Date Completed
April 1, 2020
Status
3. Completed
Research Team
EOC
Key Findings
· There are some recommendations and precautions from WHO, CDC, Canada and the UK that there is transmission of the COVID virus from the administration of nebulizer medication. · Some case studies of SARS found few instances that patients may likely be infected after aerosol generating procedures including nebulized medications, and although there are few evidences that demonstrates low risk of viral transmission from nebulizers, possibility of transmission remains
Category
Epidemiology
Infection Prevention and Control
Subject
Aerosols
Risk
Transmission
Population
All
Clinical Setting
Ambulatory
Priority Level
Level 2 completed within 8 hours
Cite As
Badea, A; Groot, G; Fenton, M; Dalidowicz, M; Young, C. What is the degree of COVID-19 transmission through the administration of nebulizer medication either in clinical practice or in animal experiments? 2020 Apr 1; Document no.: EOC040101 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 10 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC033001 RR
Question Submitted
March 30, 2020
Date Completed
March 30, 2020
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC033001 RR
Question Submitted
March 30, 2020
Date Completed
March 30, 2020
Status
3. Completed
Research Team
EOC
Key Findings
· Some countries like Taiwan and Malaysia have created their own intubation hood design as others offered to produce or modify the original design to fit their country’s equipment. · Several countries have also created innovation in airway management such as 3D printed respirator valves for hospitals and 3D printed ventilators. · An Emergency physician in Northern Italy shared that due to influx of patients in the hospitals, “intubation and invasive mechanical ventilators in the ED are reserved for patients not responsive to NIV” although in principle can give a more favorable chance for patients if given before their condition deteriorates.
Category
Infection Prevention and Control
Subject
Intubation
Aerosols
Population
All
Clinical Setting
Ambulatory
Cardiac unit
Priority Level
Level 2 completed within 8 hours
Cite As
Badea, A; Groot, G; Dalidowicz, M. Where and how are they producing and using intubation hoods? 2020 Mar 30; Document no.: EOC033001 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 7 p. (CEST rapid review report)
Similar Reviews
EOC090202 RR
Related Documents
Documents
Less detail

6 records – page 1 of 1.